Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CD19-CART in Refractory/Recurrent ALL
NCT03232619Phase 2Completed
- Sponsor
- BRL Medicine Inc.
- Start
- Aug 2018
- Primary completion
- May 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by BRL Medicine Inc. Primary endpoint: Radiological Assessment. Started Aug 2018; status: completed.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03232619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232619.